Metotrexato Generis (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This limits the replication of rapidly dividing cells, including immune cells that drive inflammation and cancer cells, thereby reducing disease activity and tumor growth.

The specific dose of Metotrexato Generis is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment response. Dosage regimens vary widely across indications, and the prescriber will tailor the amount and frequency to each individual case.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methotrexate is often considered the first‑line disease‑modifying antirheumatic drug because of its proven efficacy, oral availability, and cost‑effectiveness. Compared with biologic DMARDs, it has a broader safety profile but may require more laboratory monitoring. Choice of therapy depends on disease severity, patient comorbidities and response to prior treatments.

Metotrexato Generis should be stored at room temperature, below 25 °C, in its original packaging. The container protects the tablets from moisture and light, helping maintain potency throughout the shelf life. Do not store in humid or excessively hot environments.

Metotrexato Generis is supplied as an oral tablet that is swallowed whole with water. The prescriber will indicate whether the tablet should be taken with food or on an empty stomach, and the dosing schedule (e.g., weekly) based on the therapeutic indication.

The most serious risks include severe liver injury, pulmonary fibrosis, bone‑marrow suppression leading to anemia or infection, and rare life‑threatening allergic reactions. Patients should be monitored regularly for liver enzymes, blood counts and respiratory symptoms, and any alarming signs should prompt immediate medical evaluation.

Metotrexato Generis is contraindicated in individuals who are pregnant, nursing, or have known hypersensitivity to methotrexate. It should also be avoided in patients with severe liver disease, uncontrolled infections, or significant renal impairment unless dose adjustments and close monitoring are implemented.